2m 2m 2m 2m 2m 2m 2m
CERIBELL (CBLL)
NASDAQ
$18.40+$0.005 (+0.03%)
Price as of Jun 23, 2026 5:37 PM EDT- $689.8MMarket Cap
- -1.68%1-Year Change
- Medical DevicesIndustry
CERIBELL (CBLL)
$18.40+$0.005 (+0.03%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 67.3M +2.89% | 65.4M N/A | |
Cost of Revenue | 10.1M +16.49% | 8.7M N/A | |
Gross Profit | 78.3M +37.93% | 56.8M N/A | |
Sales and Marketing Expense | 73.1M +48.98% | 49.1M N/A | |
Research and Development Expense | -19.1M +41.15% | -13.6M N/A | |
Depreciation and Amortization Expense | 1.3M +17.53% | 1.1M N/A | |
Total Operating Expenses | 136.7M +41.69% | 96.5M N/A | |
Operating Profit | -58.4M +47.07% | -39.7M N/A | |
Interest Income | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 6.9M +150.91% | 2.7M N/A | |
Income before Taxes | -53.4M +32.03% | -40.5M N/A | |
Income Taxes | 0 -100.00% | 11,000 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -53.4M +32.03% | -40.5M N/A | |
Net Income from Continuing Operations Applicable to Common | -53.4M +32.03% | -40.5M N/A | |
Basic EPS and Net Income | -1.46 -56.93% | -3.39 N/A | |
Diluted EPS and Net Income | -1.46 -56.93% | -3.39 N/A | |
Basic Weighted Average Shares | 36.5M +205.79% | 11.9M N/A | |
Diluted Weighted Average Shares | 36.5M +205.79% | 11.9M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 40.5M -79.18% | 194.4M N/A | |
Short-Term Investments | 118.8M N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 159.3M -18.06% | 194.4M N/A | |
Total Current Assets | 186.7M -14.06% | 217.3M N/A | |
Accumulated Depreciation | 2.7M +59.93% | 1.7M N/A | |
Property and Plant and Equipment and Net | 2.0M -12.24% | 2.3M N/A | |
Total Long-Term Assets | 2.9M +33.09% | 2.2M N/A | |
Total Assets | 195.8M -13.14% | 225.4M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | 11.8M N/A | |
Total Current Liabilities | 19.2M +47.74% | 13.0M N/A | |
Total Long-Term Debt | 19.8M +1.29% | 19.6M N/A | |
Total Long-Term Liabilities | 21.3M +0.09% | 21.3M N/A | |
Total Liabilities | 40.5M +18.16% | 34.2M N/A | |
Retained Earnings | -220.4M +31.99% | -166.9M N/A | |
Total Stockholders Equity | 155.3M -18.74% | 191.2M N/A | |
Total Shares Outstanding | 37.5M +4.56% | 35.9M N/A | |
Cash Flow | |||
Cash from Operating Activities | -40.8M +16.45% | -35.0M N/A | |
Capital Expenditures | 767,000 -42.76% | 1.3M N/A | |
Cash from Investing Activities | -118.1M +7,292.80% | -1.6M N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 5.1M -97.43% | 196.5M N/A | |
Financials Ratio | |||
Gross Margin | 84.96% N/A | N/A N/A | |
Operating Margin | -86.73% N/A | N/A N/A | |
Return on Assets | -25.36% N/A | N/A N/A | |
Return on Equity | -30.83% N/A | N/A N/A | |
Revenue Growth | 2.89% N/A | N/A N/A | |
Current Ratio | 9.73 N/A | N/A N/A | |
Cash Ratio | 2.11 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow